Stromacare SAS
Georges Rawadi possesses extensive experience in the biotechnology and healthcare sectors, currently serving as CEO of Stromacare SAS since February 2024. Previously, Georges held notable positions such as Chairman of the Strategic Board and Non-Executive Board Member at Apmonia Therapeutics, Chief Executive Officer and Board Member at Celyad Oncology, and a member of the Board of Directors at Alia Therapeutics. Additional roles include Chief Biotech Studio Development at eureKARE and leadership positions at YSOPIA Bioscience, Celyad, and Cellectis. With a PhD in Microbiology from Pierre and Marie Curie University and a Master's degree in Management and Strategy from ESSEC Business School, Georges has a strong foundation in strategic consulting, business development, and intellectual property management within the biotech industry.
This person is not in any teams
Stromacare SAS
StromaCare is opening a new therapeutic avenue by targeting the tumoral Stroma, which is known to play a key role in several solid cancers, with the objective to be essential in the numerous anticancer protocols of treatment. Stromacare won the Beatrice Denys Foundation 2021 Prize (Foundation for Medical Research). The company is located in Lyon, France.